Tag: Windtree Therapeutics

Windtree Therapeutics Reports Third Quarter 2020 Financial Results and Provides Key Business Updates

Financial by 0 comments

WARRINGTON, Pa., Nov. 16, 2020 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the third quarter ended September 30, 2020 and provided key business updates. Key Business and Financial Updates Announced the dosing […]

Continue Reading →

Windtree Presents New Istaroxime Phase 2b Study Analysis at the American College of Cardiology (ACC) Congress

Coronary/Structural Heart by 0 comments

Efficacy of 24 Hour Istaroxime Infusion is Similar Between Caucasian and Asian Patients Hospitalized for Acute Heart Failure WARRINGTON, Pa., April 6, 2020 /PRNewswire/ — Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, […]

Continue Reading →

Windtree Enters into Agreement with Lee’s Pharmaceutical for Non-Dilutive Funding of the Continued Development of AEROSURF®

Financial by 0 comments

WARRINGTON, Pa., March 31, 2020 /PRNewswire/ — Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, announces it has entered into a binding term sheet (the “Term Sheet”) with Lee’s Pharmaceutical Holdings (HK) Ltd (“Lee’s”) […]

Continue Reading →

Windtree Therapeutics Completes $26.4 Million Private Placement

Financial by 0 comments

WARRINGTON, Pa., Dec. 9, 2019 /PRNewswire/ — Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced that it has completed a $26.4 million private placement of common stock and warrants. In connection with this offering, […]

Continue Reading →
1 2 3 4